SF3B1 and myelodysplastic syndrome: The MDS-RS subcategories are changed in the WHO-HAEM5 to MDS with low blasts and SF3B1 mutation (MDS-SF3B1) in patients with SF3B1 mutations, while MDS with low blasts and RS is acceptable when there are ≥ 15% RS and wild type SF3B1.